Inventor · disambiguated record
Johannes Auer
Also filed as: AUER JOHANNES
18 granted patents·17 pending applications·289 citations·filing 1993–2024
94Inventor score
Files withHOFFMANN LA ROCHE16ROCHE DIAGNOSTICS GMBH7AUER JOHANNES5ROCHE GLYCART AG2ROCHE PALO ALTO LLC2
Top patents by PatentIndex Score
35 records- 0195US6391633B1Production of erythropoietin by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 1998·Granted May 21, 2002·158 cites·22 claims
- 0293US8003099B2Antibodies against human IL17 and uses thereofROCHE PALO ALTO LLC·Filed 2009·Granted Aug 23, 2011·44 cites·17 claims
- 0391US9714292B2Bispecific antibodies against human TWEAK and human IL17 and uses thereofHOFFMANN LA ROCHE·Filed 2014·Granted Jul 25, 2017·21 cites·14 claims
- 0486US6544748B2Preparation of erythropoietin by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 2001·Granted Apr 8, 2003·10 cites·33 claims
- 0585US9346886B2Humanized anti-CDCP1 antibodiesROCHE GLYCART AG·Filed 2012·Granted May 24, 2016·8 cites·2 claims
- 0684US7214532B2Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereofROCHE DIAGNOSTICS GMBH·Filed 2003·Granted May 8, 2007·9 cites·5 claims
- 0782US10570188B2Method for producing monomeric and multimeric molecules and uses thereofHOFFMANN LA ROCHE·Filed 2017·Granted Feb 25, 2020·3 cites·3 claims
- 0880US8394928B2Humanized anti-CDCP1 antibodiesAUER JOHANNES·Filed 2010·Granted Mar 12, 2013·7 cites·33 claims
- 0977US6555373B1Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereofROCHE DIAGNOSTICS GMBH·Filed 2000·Granted Apr 29, 2003·4 cites·7 claims
- 1076US2024043564A1Anti-brdu antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1172US11673968B2Anti-BRDU antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Granted Jun 13, 2023·0 cites·3 claims
- 1271US7186529B2Preparation of erythropoietin by endogenous gene activationROCHE DIAGNOSTICS GMBH·Filed 2003·Granted Mar 6, 2007·2 cites·26 claims
- 1371US2025034663A1Method for determining aav genomesHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1469US10329346B2TNFa-IL-17 bispecific antibodiesHOFFMANN LA ROCHE·Filed 2016·Granted Jun 25, 2019·1 cites·23 claims
- 1567US11254728B2Method for producing monomeric and multimeric molecules and uses thereofHOFFMANN LA ROCHE·Filed 2020·Granted Feb 22, 2022·0 cites·11 claims
- 1659US6284541B1Positive-negative selection for homologous recombinationROCHE DIAGNOSTICS GMBH·Filed 1998·Granted Sep 4, 2001·12 cites·32 claims
- 1759US2022169729A1Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organizationHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1859US2017114150A1Anti-brdu antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 1959US2022169731A1Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organizationHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2054US6548296B1Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereofROCHE DIAGNOSTICS GMBH·Filed 1998·Granted Apr 15, 2003·6 cites·15 claims
- 2154US2024002538A1Method for the assembly of large nucleic acids from short fragmentsHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2253US2022169730A1Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organizationHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2352US7754448B2Method for the recombinant expression of an N-terminal fragment of hepatocyte growth factorHOFFMANN LA ROCHE·Filed 2005·Granted Jul 13, 2010·0 cites·7 claims
- 2452US2008319165A1Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least one neuropeptideNEURAXO BIOTEC GMBH·Filed 2008·Application pending·0 cites
- 2546US2017198043A1Bispecific antigen binding moleculesROCHE GLYCART AG·Filed 2016·Application pending·0 cites
- 2646US2021139561A1Method for the generation of a multivalent, multispecific antibody expressing cells by targeted integration of multiple expression cassettes in a defined organizationHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2745US11680110B2Three-dimensional structure-based humanization methodHOFFMANN LA ROCHE·Filed 2018·Granted Jun 20, 2023·0 cites·2 claims
- 2845US2009226434A1Afucosylated antibodies against CCR5 and their use for the treatment of inflammatory conditionsROCHE PALO ALTO LLC·Filed 2009·Application pending·0 cites
- 2945US2015218250A1Method for producing monomeric and multimeric molecules and uses thereofHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 3044US2003215792A1Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least on neuropeptideHANS WERNER MUELLER·Filed 2002·Application pending·0 cites
- 3143US2013058937A1Bispecific antigen binding moleculesAUER JOHANNES·Filed 2012·Application pending·0 cites
- 3242US2009110686A1Antibodies against CCR5 and uses thereofAUER JOHANNES·Filed 2007·Application pending·0 cites
- 3340US5354669AType II restriction endonuclease SexAIBOEHRINGER MANNHEIM GMBH·Filed 1993·Granted Oct 11, 1994·4 cites·10 claims
- 3439US2013195844A1Antibodies against human il17 and uses thereofAUER JOHANNES·Filed 2011·Application pending·0 cites
- 3536US2012020988A1Antibodies specifically binding to human TSLPR and methods of useAUER JOHANNES·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →